LIN vs ROIV · P/E 34, rev $33.99B vs rev $29.1M
Linde plc Ordinary Shares (LIN) versus Roivant Sciences Ltd (ROIV) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Roivant Sciences Ltd (ROIV) is a biotechnology company listed on US.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Latest reported ROIV revenue for 2025-03-31 was $29.1M. Net income was -$356.7M. Revenue was down 11.2% from 2024-03-31 to 2025-03-31. ROIV currently screens at market cap $7.47B.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. ROIV currently screens at market cap $7.47B.
Not investment advice. Open the LIN and ROIV stock pages for the full models.
Not investment advice.